GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InspireMD Inc (NAS:NSPR) » Definitions » ROE %
中文

InspireMD (InspireMD) ROE %

: -52.25% (As of Dec. 2023)
View and export this data going back to 1997. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. InspireMD's annualized net income for the quarter that ended in Dec. 2023 was $-21.62 Mil. InspireMD's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $41.38 Mil. Therefore, InspireMD's annualized ROE % for the quarter that ended in Dec. 2023 was -52.25%.

The historical rank and industry rank for InspireMD's ROE % or its related term are showing as below:

NSPR' s ROE % Range Over the Past 10 Years
Min: -1539.76   Med: -126.02   Max: -62.09
Current: -62.09

During the past 13 years, InspireMD's highest ROE % was -62.09%. The lowest was -1,539.76%. And the median was -126.02%.

NSPR's ROE % is ranked worse than
80.27% of 811 companies
in the Medical Devices & Instruments industry
Industry Median: 0.25 vs NSPR: -62.09

InspireMD ROE % Historical Data

The historical data trend for InspireMD's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InspireMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -141.95 -120.19 -65.29 -72.62 -70.01

InspireMD Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -98.72 -110.48 -67.42 -45.99 -52.25

Competitive Comparison

For the Medical Devices subindustry, InspireMD's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InspireMD ROE % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's ROE % distribution charts can be found below:

* The bar in red indicates where InspireMD's ROE % falls into.



InspireMD ROE % Calculation

InspireMD's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-19.916/( (17.393+39.501)/ 2 )
=-19.916/28.447
=-70.01 %

InspireMD's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-21.62/( (43.257+39.501)/ 2 )
=-21.62/41.379
=-52.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


InspireMD  (NAS:NSPR) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-21.62/41.379
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-21.62 / 7.044)*(7.044 / 48.8315)*(48.8315 / 41.379)
=Net Margin %*Asset Turnover*Equity Multiplier
=-306.93 %*0.1443*1.1801
=ROA %*Equity Multiplier
=-44.29 %*1.1801
=-52.25 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-21.62/41.379
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-21.62 / -21.36) * (-21.36 / -23.232) * (-23.232 / 7.044) * (7.044 / 48.8315) * (48.8315 / 41.379)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0122 * 0.9194 * -329.81 % * 0.1443 * 1.1801
=-52.25 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


InspireMD ROE % Related Terms

Thank you for viewing the detailed overview of InspireMD's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


InspireMD (InspireMD) Business Description

Traded in Other Exchanges
N/A
Address
4 Menorat Hamaor Street, Tel Aviv, ISR, 6744832
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Germany, Italy, Belarus, Brazil, and other countries.
Executives
Gary S Roubin director 4300 ROCKMORE RD JACKSON, WYOMING WY 83001
Patrick Verta officer: EVP Clinical/Medical Affairs 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN 55344
Michael Berman director 735 PALAMAR AVENUE, SUNNYVALE CA 94085
Thomas J Kester director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Paul Stuka director C/O OSIRIS PARTNERS, LLC, ONE LIBERTY SQUARE, 5TH FLOOR, BOSTON MA 02109
Andrea Tommasoli officer: Chief Operating Officer 22, RUE DE LA PLAGE, COLLONGES AU MONT D OR I0 69660
Shane Thomas Gleason officer: VP Global Marketing 18 NORTHAMPTON PL, COTO DE CAZA CA 92679
Kathryn Arnold director 1136 CHESTNUT AVE., WILMETTE IL 60091
Marvin Slosman director, officer: CEO and President 4 MENORAT HAMAOR ST., C/O INSPIREMD, INC., TEL AVIV L3 6744832
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Agustin V Gago officer: EVP, Chief Commercial Officer 256 JERUSALEM AVE, MASSAPEQUA NY 11758
Eric L. Olson officer: VP of Global Sales Operations C/O INSPIREMD, INC., 800 BOYLSTON STREET, 16TH FLOOR, BOSTON MA 02199
Campbell Rogers director C/O INSPIREMD, INC., 800 BOYLSTON STREET, SUITE 16041, BOSTON MA 02199
James J Barry director C/O INSPIREMD, INC., 4 MENORAT HAMAOR ST., TEL AVIV L3 6744832
Eyal Weinstein director C/O LEOREX LTD., P.O.B. 15067 MATAM, HAIFA L3 31905